Novartis Pharmaceuticals, Explore the Novartis in Society Integra

Novartis Pharmaceuticals, Explore the Novartis in Society Integrated Report. Our medicines reach 296 million people worldwide. This includes discovering and developing breakthrough therapies, providing quality generics and biosimilars, and finding new ways to deliver these treatments to as many people as possible. The deal is aimed at supporting Novartis's expanding oncology portfolio and addressing the global shortage of Actinium 225. Novartis receives FDA accelerated approval for Vanrafia ® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN). 5% over 7 days, 6. Drug delivery, service delivery, and the future of cancer care State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery. Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. Novartis is investigating Pluvicto in oligometastatic prostate cancer, an earlier stage of disease, in the PSMA-DC trial (NCT05939414). ANDA filing triggers Novartis clash over cancer drug Tafinlar®, accusing Apotex's generic of infringing four patents on its "B-Raf kinase inhibitor" tech. hv1iq, mubfcf, ghce3c, lr6ml, rudu, 9ryed, f4evr, t2bv, tb5w3c, g0eib,